Drug Search Results

PD-217,014

Alternative Names: pd-217,014, pd217,014, pd 217,014
Latest Update: 2024-05-16
Latest Update Note: PubMed Publication

Product Description

the treatment of abdominal pain/discomfort associated with irritable bowel disease

Mechanisms of Action: GABA Analogue

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PD-217,014

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Irritable Bowel Syndrome|Neuralgia, Postherpetic

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
A4451007	P2	Completed	Irritable Bowel Syndrome	2005-02-01
A4451006	P2	Terminated	Neuralgia, Postherpetic	None

Recent News Events

Date	Type	Title
05/16/2024	PubMed	Epicardial fat volume is associated with primary coronary slow-flow phenomenon in patients with severe aortic stenosis undergoing transcatheter valve implantation.
05/15/2024	PubMed	Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer.
05/15/2024	PubMed	Non-specific uptake of 18F-FAPI-04 in the pancreas and its related factors: a post-hoc analysis of an ongoing prospective clinical trial.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions